Soligenix Inc (SNGX)

Jan 16, 2025, 7:30 AM EST - 1 day ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 3 days ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 4 weeks ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 6 weeks ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 2 months ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 2 months ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 2 months ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 2 months ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Oct 22, 2024, 7:30 AM EDT - 3 months ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 16, 2024, 7:30 AM EDT - 3 months ago

Soligenix Invited to Present at Upcoming Investor Conferences

Oct 7, 2024, 7:30 AM EDT - 3 months ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Oct 3, 2024, 7:30 AM EDT - 3 months ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Sep 20, 2024, 9:00 AM EDT - 4 months ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Sep 16, 2024, 7:30 AM EDT - 4 months ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Sep 3, 2024, 7:30 AM EDT - 4 months ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Aug 16, 2024, 9:00 AM EDT - 5 months ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

AREC

Aug 9, 2024, 7:30 AM EDT - 5 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Jul 15, 2024, 10:16 AM EDT - 6 months ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

Jul 9, 2024, 12:46 PM EDT - 6 months ago

Soligenix stock rallies 400% on positive HyBryte trial results

Jul 9, 2024, 12:11 PM EDT - 6 months ago

Crude Oil Down 1%; Soligenix Shares Surge

Jul 9, 2024, 11:38 AM EDT - 6 months ago

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Jul 9, 2024, 7:30 AM EDT - 6 months ago

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jun 25, 2024, 7:30 AM EDT - 7 months ago

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Jun 14, 2024, 7:30 AM EDT - 7 months ago

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

Jun 7, 2024, 9:00 AM EDT - 8 months ago

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

STSS

May 31, 2024, 7:30 AM EDT - 8 months ago

Soligenix Announces Reverse Stock Split

May 29, 2024, 7:30 AM EDT - 8 months ago

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

May 24, 2024, 7:30 AM EDT - 8 months ago

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

May 23, 2024, 7:30 AM EDT - 8 months ago

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

May 21, 2024, 7:30 AM EDT - 8 months ago

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

May 20, 2024, 7:30 AM EDT - 8 months ago

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

May 16, 2024, 7:30 AM EDT - 8 months ago

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

May 10, 2024, 7:30 AM EDT - 9 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

May 6, 2024, 7:30 AM EDT - 9 months ago

Soligenix to Present at Upcoming Conferences

Apr 25, 2024, 7:30 AM EDT - 9 months ago

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Apr 18, 2024, 8:30 AM EDT - 9 months ago

Soligenix Announces Pricing of $4.75 Million Public Offering

Apr 15, 2024, 7:30 AM EDT - 9 months ago

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Apr 11, 2024, 7:30 AM EDT - 10 months ago

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

Apr 3, 2024, 7:30 AM EDT - 10 months ago

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

Mar 15, 2024, 7:30 AM EDT - 11 months ago

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

Feb 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

Jan 26, 2024, 9:00 AM EST - 1 year ago

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

Jan 25, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at The Microcap Conference

Jan 8, 2024, 7:30 AM EST - 1 year ago

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Jan 4, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Jan 2, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Dec 1, 2023, 7:30 AM EST - 1 year ago

"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery

Nov 30, 2023, 7:30 AM EST - 1 year ago

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease

Nov 13, 2023, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results

Oct 20, 2023, 9:00 AM EDT - 1 year ago

ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ASPI